Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

108
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
108
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

308
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
308
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

175
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
175
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

179
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
179
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

235
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
235
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

208
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same author

Overcoming barriers to deliver high quality kidney care.

Nature reviews. Nephrology·2024
Same author

Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research.

Canadian journal of kidney health and disease·2024
Same author

Kidney biopsies among persons living in hotspots of CKDu: a position statement from the International Society of Nephrology's Consortium of Collaborators on CKDu.

Kidney international·2023
Same author

Patient and Clinician Experiences With the Combination of Virtual and In-Person Chronic Kidney Disease Care Since the COVID-19 Pandemic.

Canadian journal of kidney health and disease·2023
Same author

Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward?

Journal of the American Society of Nephrology : JASN·2023

Related Experiment Video

Updated: Dec 4, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.0K

Alport Syndrome Classification and Management.

Bradley A Warady1, Rajiv Agarwal2, Sripal Bangalore3

  • 1Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, MO.

Kidney Medicine
|October 23, 2020
PubMed
Summary

Alport syndrome, a rare genetic kidney disease, may affect more people than previously thought. New classifications link it to thin basement membrane nephropathy and focal segmental glomerulosclerosis, highlighting inflammation

Keywords:
Alport syndromeCOL4A3COL4A4COL4A5NF-κBNrf2chronic inflammationchronic kidney disease

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

18.2K

Related Experiment Videos

Last Updated: Dec 4, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.0K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

18.2K

Area of Science:

  • Nephrology and Genetics
  • Molecular Biology and Immunology

Background:

  • Alport syndrome, a genetic disorder affecting type IV collagen, impacts up to 60,000 individuals in the US.
  • Thin basement membrane nephropathy and focal segmental glomerulosclerosis may be reclassified under Alport syndrome, expanding the affected population.
  • Genetic evaluation categorizes Alport syndrome into X-linked, autosomal, and digenic forms based on type IV collagen α3/4/5 mutations.

Purpose of the Study:

  • To propose a reclassification of Alport syndrome based on genetic evaluation of type IV collagen α3/4/5.
  • To identify patients at risk for progressive kidney function loss.
  • To explore the role of chronic inflammation and transcription factors Nrf2 and NF-κB in Alport syndrome pathogenesis.

Main Methods:

  • Genetic evaluation of mutations in COL4A3, COL4A4, and COL4A5 genes.
  • Analysis of downstream pathophysiologic consequences, including chronic kidney inflammation.
  • Review of recent evidence on the regulation of inflammation by Nrf2 and NF-κB pathways in chronic kidney disease.

Main Results:

  • Shared molecular causes between Alport syndrome and thin basement membrane nephropathy involve mutations in COL4A3, COL4A4, and COL4A5.
  • Chronic inflammation, regulated by Nrf2 and NF-κB, plays a key role in renal cell injury and disease progression.
  • An insufficient Nrf2 response to inflammation is linked to the progression of chronic kidney disease.

Conclusions:

  • Reclassifying certain kidney diseases as Alport syndrome based on genetics can identify at-risk populations.
  • Type IV collagen abnormalities are associated with chronic inflammation, suggesting a common pathway in kidney disease.
  • Targeted anti-inflammatory therapies are of renewed interest for Alport syndrome and progressive chronic kidney diseases.